Association of low levels of first trimester Pregnancy Associated Plasma Protein (PAPP-A) with adverse pregnancy outcomes: An observational study

Archana Ranganathan¹*, John Fresen² and Pampa Sarkar³

¹Registrar Obstetrics and Gynaecology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK
²Department of IT Services, University of Oxford, 13 Banbury Road, Oxford OX2 6NN, England, UK
³Consultant Obstetrician and Gynaecologist, Frimley Health Foundation Trust, Wexham Park Hospital Wexham, Slough, Berkshire, UK

Abstract

Objectives: To explore the effects of low levels of first trimester Pregnancy Associated Plasma Protein-A (PAPP-A) on adverse pregnancy outcomes.

Design: Single centre retrospective observational study.

Setting: District general hospital.

Population: Women with singleton pregnancies with low PAPP-A, attending Heatherwood and Wexham Park Hospital for first trimester combined screening for Down syndrome.

Methods: Data was collected from Astraia Database and CMiS maternity system. Multiple linear regression models for birth weight and gestational age at delivery were developed after adjusting for confounding variables. Logistic regressions were dichotomised for preterm delivery into <34 weeks and ≥ 34 weeks, birth weight centiles, into <10th centile and ≥10th centile, and pre-eclampsia versus no pre-eclampsia.

Main outcome measures: Preterm birth, small for gestational age (SGA) and pre-eclampsia.

Results: PAPP-A levels of ≤0.4MoM is associated with SGA <10th centile at p=0.04 with a positive predictive value (PPV) of 83.3% and negative predictive value (NPV) of 79.3%. Similarly, association with preterm birth <34 weeks is also significant at p=0.05 with PPV of 66% and NPV of 87.4%. A significant association with pre-eclampsia (p=0.6) could not be identified. In our study data of PAPP-A ≤0.4 MoM, for every 0.1MoM fall in PAPP-A, there was a reduction in birth weight by 78gm and an earlier birth by 5.3 days.

Conclusion: There is an increased likelihood of preterm delivery and SGA with progressive reduction of PAPP-A levels below ≤0.4 MoM.

Introduction

Pregnancy Associated Plasma Protein (PAPP-A) is an important glycoprotein found in maternal blood that increases as pregnancy progresses [1], although it is not specific to pregnancy [2,3]. In pregnancy, PAPP-A is principally expressed in the syncytiotrophoblast of the placenta, which forms the main source of circulating maternal PAPP-A [4-6]. PAPP-A first identified in 1974, was later shown to be a protease that cleaves insulin-like growth factor binding protein -4 and -5 (IGFBP-4 and -5) to release free Insulin-like Growth Factors (IGF-1 and IGF-2) [7-9], and known to play a critical role in the regulation of fetal and placental growth [10-12]. Insulin-like Growth Factors (IGFs) are also thought to have an important role in the autocrine and paracrine control of trophoblast invasion of the decidua [13]. Maternal serum PAPP-A concentrations reflect the placental volume; hence low levels of PAPP-A may be an indicator of impaired placental function and implantation. Reduced placental size and defective syncytiotrophoblast results in reduced secretion of PAPP-A [14,15]. The origins of fetal growth restriction, as well as pre-eclampsia, known to be associated with placental dysfunction, are reported to occur in the 1st trimester, probably due to poor placentalation secondary to suboptimal trophoblastic invasion [16]. In keeping with this logic, there is emerging evidence that low PAPP-A is associated with adverse pregnancy outcomes such as pregnancy loss, preterm birth and low birth weight [17,18].

Maternal serum PAPP-A levels in the first trimester are readily available in recent years due to well-established first trimester combined screening test for trisomy 21. Low PAPP-A levels are associated with an increased risk of chromosomal aberrations [19-21]. In addition to its value in predicting aneuploidy, decreased PAPP-A levels in chromosomally normal fetuses are associated with various adverse pregnancy outcomes; however not sufficiently enough to be a marker for prediction of any one outcome.
The aim of this study was to explore and quantify the effects of low levels of first trimester PAPP-A on pregnancy outcomes, in particular Small for Gestational Age (SGA), preterm birth and development of pre-eclampsia.

**Methods**

This is a single centre retrospective observational study of singleton pregnancies that underwent first trimester combined screening for Down syndrome between January 2011 and December 2013 at the then Heatherwood and Wexham Park Hospitals Foundation Trust, now part of Frimley Health Foundation Trust. Pregnancy outcome data were collected until June 2014. From this cohort of women, all singleton pregnancies with PAPP-A levels ≤0.4 MoM (corresponding to 5th centile) were identified from the Astraia Obstetrics ultrasound database (www.astraia.com) with documentation and risk estimates of first trimester screening. Data regarding maternal characteristics, biomarkers, ultrasound measures and pregnancy outcomes were also collected from Astraia. This included maternal age, weight, Body Mass Index (BMI), smoking status, ethnicity, mode of conception, parity, PAPP-A in MoM, as well as outcomes including Gestational Age (GA) at delivery, mode of delivery and birth weight (live births). This information was cross-referenced with that on CMIS Maternity database (HD Clinical). CMIS database was also searched to identify any pre-existing hypertension or diabetes, subsequent development of gestational hypertension, Pre-Eclampsia (PET), or Gestational Diabetes (GDM) in these women. The birth weight centile was calculated adjusting for GA at delivery.

PAPP-A levels were measured using Thermo Fisher Scientific, Brahms Kryptor analyser. This is based on Time Resolved Amplified Cryptate Emission (TRACE) technology. Astraia converts the absolute values of PAPP-A into MoM, adjusting for fetal Crown Rump Length (CRL), maternal age, maternal weight, parity, ethnicity, smoking and use of assisted conception techniques as previously described by Kagan et al [22]. CRL and nuchal translucency (NT) measurements were assessed by trained sonographers according to guidelines outlined by Fetal Medicine Foundation [23,24] and FASP (Fetal Anomaly Screening Programme). GA was calculated from first trimester CRL.

Miscarriage was defined as fetal loss prior to 24 weeks of gestation. Preterm birth was defined as birth before 37 completed weeks of gestation (and after 24 weeks of gestation), which could be either iatrogenic or due to spontaneous preterm labour, and early preterm birth defined as that before 34 weeks of gestation. Pre-eclampsia was defined, according to the guidelines of the International Society for the Study of Hypertension in Pregnancy [25], as the occurrence of gestational hypertension with proteinuria of 300 mg or more in 24 hours or two readings of elevated blood pressure and at least 2+ on the urine dipstick analysis 6 hours apart. SGA was defined as a birth weight below the 10th centile for gestational age [26].

**Statistical analyses**

Statistical analyses were performed using the R software for statistical computing and graphics, version 3.2.1. Histograms and bar charts of the variables were examined to understand the distribution of the data, and consider the possible need for transformation, to check for outliers and influential observations, and to identify sparse categories that may require recoding. A scatter plot matrix of the continuous variables was drawn to determine rough linear or non-linear relationships in the data. The continuous variables included age, body mass index (BMI), PAPP-A, Gestational Age (GA) at delivery and birth weight. All the above variables except PAPP-A were approximately normally distributed; the distribution GA at birth is skewed to the left. Due to experimental conditions, PAPP-A formed the left tail of normal distribution. Boxplots and violin plots were drawn for the categorical/discrete predictors, which included pre-eclampsia, gestational diabetes, parity, smoking status and ethnicity. Bivariate analyses were performed to explore important predictors for each of our primary outcomes. The data were analysed using both linear regression (with gestational age at delivery and birth weight as continuous variables) and logistic regressions dichotomised for preterm delivery into <34 weeks, SGA dichotomised for <10th centile, and pre-eclampsia versus no pre-eclampsia. Multiple linear regression models for birth weight and gestational age at delivery were developed adjusting for confounding variables. The performances of the different models were evaluated by Receiver Operating Characteristic (ROC) curve analysis with estimation of areas under the curve (AUROC). The quality-of-fit of models was assessed using $r^2$ and AIC (Akaike Information Criterion) [27]. Sensitivity, specificity, and predictive values were obtained for the logistic regression models. In all regression models, we used LARS (Least Angle Regression) using the lasso option, to select the variables. We considered a p value <0.05 as significant, adjusted using the Bonferroni correction for simultaneous inference.

**Results**

A total of 17,215 women were booked during the study period and 13,662 women underwent first trimester combined screening for trisomy 21. A total of 492 singleton pregnancies were identified with PAPP-A levels ≤0.4MoM. We excluded 19 women who had spontaneous miscarriage before 14 weeks of gestation, 7 pregnancies that were terminated (4 for Trisomy 21, 2 for trisomy 18, and one for trisomy 13), and 490 women delivered elsewhere and were considered lost to follow up. We did not impute 16 women who had missing data considering the excess of imputation required. The data from the remaining 418 women with low PAPP-A were analysed. The data is available in an anonymised form and is stored in an encrypted excel spreadsheet with the authors.

Tables S1 and S2 summarises the characteristics and outcomes of the study group are available online as supporting information. 94 (22.4%) babies were born SGA (<10th centile) amongst which 59 (14.1%) were <5th centile. There were 54 (12.9%) preterm births (GA <37 weeks) of which 16 (3.8%) were early preterm births (GA <34 weeks). Multiple linear regression models and logistic regression models for birth weight and GA at delivery were drawn (Tables 1 and 2). In linear regression models, PAPP-A was found to be a significant predictive factor for birth weight (p=0.01), and GA at delivery (p=0.02). The logistic regression model of SGA <10th centile and early preterm births (<34 weeks) demonstrated statistically significant association with PAPP-A at p= 0.041 and p=0.05 respectively.

Sensitivity, specificity, predictive values and area under the curve (AUC) of the logistic regression models are shown in Table 3. Figures 1a and 1b portray the estimated probability due to the fitted model. Figure 1a reflects the probability of SGA in terms of PAPP-A and GA at birth applied to each data point. Figure 1b illustrates how the probability changes for all values of PAPP-A and GA at birth. Figure S1 in supporting information shows the ROC and area under the curve for PAPP-A MoMs with early preterm birth and SGA <10th centile.
Discussion

Main findings

In this study, we have demonstrated that low maternal circulating concentration of PAPP-A at 11–14 weeks of gestation significantly predicts adverse perinatal outcomes for SGA and preterm birth. We have considered the evidence available on the effect of PAPP-A on each of our primary outcomes.

In the multiple linear regression model for birth weight, PAPP-A was a highly significant predictive factor at \( p=0.01 \) after adjusting for confounding factors namely, GA at delivery, gestational diabetes, ethnicity, pre-eclampsia, parity and smoking status (Table 1). For our data, in which PAPP-A was less than 0.4MoM, it was found that for each 0.1 MoM reduction in PAPP-A, the expected decrease in birth weight was 78 gm. The adjusted \( r^2 \) for this model was 60%.

Multivariate logistic regression model demonstrate that PAPP-A is associated with high probability (\( p=0.04 \)) of SGA <10th centile (Table 1). Review of the literature on the effects of PAPP-A on SGA and preterm birth is more conflicting. Some early studies did not demonstrate significant association of PAPP-A with SGA [28,29] or preterm birth [29-32] whereas others showed strong association with SGA but not preterm birth [30-32]. However, more recently, larger studies have shown a significant association between PAPPA-A and SGA [17,33-36], preterm birth <37 weeks [17,34,36-39] and early preterm birth <34 weeks [33,34,37-40]. However, this association does not translate to prediction. On the contrary, in some studies PAPP-A has been shown to be a poor predictive factor for SGA. In the FASTER trial, PAPP-A had a positive predictive value of only 18.7% with a sensitivity of 10.4% and a negative predictive value of 91.3% for small for gestational age (<10th percentile) [17]. Pihl et al. [41] inferred that it is possible to detect fetuses being SGA at delivery with a Detection Rate (DR) of only 39% for a False Positive Rate (FPR) of 10% using the combination of PAPP-A with other biochemical markers such as βhCG and ADAM12.

The dependence of GA at delivery on PAPP-A levels was statistically significant (\( p=0.026 \)) in a linear model (Table 2) after adjusting for confounding factors namely, GA at delivery, gestational diabetes, ethnicity, pre-eclampsia, parity and smoking status, and adjusting for pre-eclampsia, maternal diabetes and mode of conception also influence GA at delivery.

Table 1. Models for birth weight

| Variables        | Standard Error | t-value | p-value |
|------------------|----------------|---------|---------|
| (Intercept)      | 346.70         | -14.23  | <2e-16**|
| PAPP-A           | 305.24         | 2.55    | 0.01*   |
| GA at delivery   | 8.91           | 22.21   | <2e-16***|
| Gestational Diabetes | 64.06    | 2.30    | 0.02    |
| Parity           | 43.59          | 4.11    | 4.7e-05 |
| Ethnicity        | 43.33          | -3.78   | 0.0001  |

Adjusted \( r^2 = 60\% \)

Logistic regression model for birth weight <10th centile

| Variables        | Standard Error | t-value | p-value |
|------------------|----------------|---------|---------|
| (Intercept)      | 1.93           | 3.63    | 0.00027 |
| PAPP-A           | 1.72           | -2.04   | 0.041*  |
| GA at delivery   | 0.007          | -3.66   | 0.0002**|
| Parity           | 0.24           | -1.66   | 0.09    |
| Smoking          | 0.32           | 1.66    | 0.96    |

Null deviance: 444.60 on 417 degrees of freedom, AIC: 427.18

*PAPP-A is significantly associated with birth weight. **Gestational age at delivery is highly significant in this model.

Table 2. Models for Gestational age (GA) at delivery

| Variables        | Standard Error | t-value | p-value |
|------------------|----------------|---------|---------|
| (Intercept)      | 0.55           | 67.66   | <2e-16**|
| PAPP-A           | 1.68           | 2.22    | 0.02*   |
| Mode of conception | 0.53      | -2.55   | 0.01    |
| Gestational Diabetes | 0.35     | -2.45   | 0.01    |
| Pre-eclampsia    | 0.32           | -3.32   | 0.0009  |

Adjusted \( r^2 = 6.12\% \)

Logistic regression model for GA at delivery <34 weeks

| Variables        | Standard Error | t-value | p-value |
|------------------|----------------|---------|---------|
| (Intercept)      | 0.96           | -1.61   | 0.10    |
| PAPP-A           | 3.16           | -1.95   | 0.05*   |
| Pre-eclampsia    | 0.56           | 1.87    | 0.06    |

Null deviance: 135.79 on 417 degrees of freedom, AIC: 135.48

**The model is highly significant. *PAPP-A significant in both models. Pre-eclampsia, maternal diabetes and mode of conception also influence GA at delivery.
for gestational diabetes, pre-eclampsia, and mode of conception. Maternal age and smoking status were not statistically significant and were removed from this model. Although the model was statistically significant, the adjusted $r^2$ was 6.12%. For every fall in PAPP-A by 0.1 MoM, the GA at delivery decreases by 5.3 days. However, when the same model was adjusted for birth weight, the significance of the effect of PAPP-A on gestational age at birth dropped to $p=0.9$, although the model was highly statistically significant with an adjusted $r^2$ was 59%. We infer that, given that PAPP-A has significant effect on birth weight, there is interplay of relationships between PAPP-A, birth weight and GA at delivery. All three factors are strongly interlinked, and it is not possible to draw meaningful conclusions upon adjusting effects on each other.

We then constructed a multivariate logistic regression model dichotomised for preterm births <34 and <37 weeks. We found that the effect of PAPP-A was significant ($p=0.05$) for preterm births <34 weeks but not <37 weeks. Hence it appears that low PAPP-A is associated with early preterm birth. The logistic regression model for preterm births <34 weeks on PAPP-A, pre-eclampsia and mode of conception is demonstrated in Table 2. There is conflicting evidence on the predictive value of PAPP-A on preterm delivery depending on the models used in the studies. For example, Beta et al. [40] observed that for prediction of spontaneous early preterm delivery, the detection rate achieved by maternal characteristics and obstetric history was not significantly improved by addition of PAPP-A MoM. Stout et al. [38] stated that for early preterm birth, in prediction models using placental protein 13 (PP-13), mean uterine artery PI (UtA-PI), maternal characteristics either alone or in combination, inclusion of PAPP-A only slightly improved the predictive utility of the models. Other earlier studies of PAPP-A and preterm delivery have found relatively low predictive values for this measure [17,42,43].

We also examined the effects of low levels of PAPP-A in the development of pre-eclampsia in our study population by creating a logistic regression model using parity, BMI, extremes of maternal age, mode of conception, ethnicity (i.e. age <20 and >40 years). PAPP-A was not statistically significant in the model but raised BMI and nulliparity were highly significant.

Ong et al. [30] in 2000 demonstrated low maternal serum PAPP-A at 10-14 weeks of gestation in pregnancy-induced hypertension. In subsequent studies, combinations of biochemical markers and sonographic markers along with PAPP-A have been studied. Although some studies have suggested an association between PAPP-A and the subsequent risk of pre-eclampsia [18,32,43-46], Scapozzio et al.[47] found the association of PAPP-A with pre-eclampsia to be weak and became non-significant when combined with free-HCG at 8-12 weeks, blood pressure and UtA-PI at 11.0-13.6 weeks. Additionally, Poon et al. [48] reported that PAPP-A did not contribute much to the prediction of late pre-eclampsia, even when combined with maternal factors, uterine artery PI and mean arterial pressure (MAP) [48]. Foidart et al. [49] showed that PAPP-A levels significantly dropped in early not late pre-eclampsia. Despite this, the detection rate of early pre-eclampsia did not improve with the addition of PAPP-A to UtA-PI and sEng (soluble endoglin) to the analysis. Giguere et al. [50] observed that the combination of two clinical characteristics and four biochemical markers (sFlt-1, PlGF, PAPP-A and inhibit A) could not out-perform a logistic model using two clinical characteristics alone, namely pre-pregnancy BMI and MAP at first prenatal visit. Recently, Wright et al. [51] reported the detection rate of preterm pre-eclampsia marginally improved from 45% with maternal characteristics to 51% with PAPP-A. Current evidence indicates that PAPP-A as a one-time single marker test for prediction of pre-eclampsia has limited value [43].

We consider the strengths in our study to include that all women had pregnancy dated accurately in the 1st trimester, calculated consistently by CRL between 11 and 13+6 weeks. Secondly, the levels of serum markers did not influence clinical management. Our population was of multi-ethnic origin and this enables generalisation of findings. We used a robust statistical approach to design a linear regression model to determine the association of PAPP-A with the primary outcome measures, after adjusting for important covariates such as smoking status, maternal age that could be influential. Our study results are in close agreement with the observations made by several other studies, and in addition to this, it also provides an estimate of the effect size of PAPP-A level on birth weight and gestational age at delivery. To our knowledge this is the first study to measure the quantitative effect of PAPP-A on birth weight and GA at delivery.

### Limitations

The study is not without limitations, including the small sample size and small range of PAPP-A values ≤0.4 MoM has limited our ability to detect its full range of effects, and that the number of pregnancies that developed pre-eclampsia were small.

### Conclusion

The association of PAPP-A levels ≤0.4 MoM with SGA and early preterm birth is statistically significant. However, a significant association with pre-eclampsia was not identified. The likelihood of an adverse outcome increases as the PAPP-A level decreases, but it is not sufficiently predictive to be used clinically on its own.

Given the inter-dependence of PAPP-A, GA at delivery and birth weight, perhaps future research methodology should include structural equation models of these variables, which may give a more realistic approximation to the process.

### Acknowledgements

Ms Joanne Bastin, Senior Sonographer ran the search in Astraia database.

### Authorship and Contributor ship

PS and AR conceived and designed the study. AR collected the data and along with JF analysed the data. JF, AR and PS were involved with interpretation of the results. AR wrote the manuscript, JF and PS commented on and contributed to the revision of drafts and final version of the article.

### Details of Ethics Approval

This study was registered with the Department of clinical audit at Heatherwood and Wexham Park Hospital and received approval to retrieve information from electronic records (CMiS and Astraia). The procedures used were in accordance with the guidelines of the Helsinki Declaration on Human Experimentation and the Good Clinical Practice (GCP) guidelines.

---

**Table 3. Prediction of pregnancy outcomes by low PAPP-A**

|                      | Sensitivity | Specificity | Positive predictive value | Negative predictive value | AUC |
|----------------------|-------------|-------------|---------------------------|---------------------------|-----|
| Preterm birth <34 weeks | 3.7%        | 99.7%       | 66%                       | 87.4%                     | 0.58|
| Birth weight <10th centile | 10%        | 99.4%       | 83.3%                     | 79.3%                     | 0.59|
References

1. Lin T, Halbert S, Kiefer D, Spellacy W (1974) Three pregnancy-associated human plasma proteins: purification, monospecific antisera and immunological identification. Int Arch Allergy 47: 35-53.

2. Bischof P, Martin-du-Pan R, Lauber K, Girard J, Herrmann W, et al. (1983) Human Seminal Plasma Contains a Protein that Shares Physicochemical, Immunochemical, and Immunosuppressive Properties with Pregnancy-Associated Plasma Protein-A. J Clin Endocrinol Metab 56: 359-362. [Crossref]

3. DuBerg S, Bischof P, Schindler A, Beguin F, Herrmann W, et al. (1982) Tissue and plasma concentrations of pregnancy-associated plasma protein-A (PAPP-A): comparison with other fetoplastic proteins. J Biochem 89: 352-357.

4. Bonno M, Oxvig C, Kephart GM, Wagner JM, Kristensen T, et al. (1994) Localization of pregnancy-associated plasma protein-A and colocalization of pregnancy-associated plasma protein-A messenger ribonucleic acid and cosinophil granule major basic protein messenger ribonucleic acid in placenta. Lab Invest 71: 560-566. [Crossref]

5. Chemnitz J, Tornhave D, Teisner B, Poulsen HK, Westergaard JG (1984) The localization of pregnancy proteins (hPL, SP1 and PAPP-A) in intra- and extraterine pregnancies. Placenta 5: 489-494. [Crossref]

6. Lin TM, Halbert SP, Spellacy WN (1974) Measurement of pregnancy-associated plasma proteins during human gestation. J Clin Invest 54: 576-582. [Crossref]

7. Lawrence JR, Oxvig C, Overgaard MT, Sotrup-Jensen L, Gleich GJ, et al. (1999) The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci U S A 96: 3149-3153. [Crossref]

8. Overgaard MT, Boldt HB, Laursen LS, Sotrup-Jensen L, Conover CA, et al. (2001) Pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase. J Biol Chem 276: 21849-21853. [Crossref]

9. Laursen LS, Overgaard MT, Soe R, Boldt HB, Sotrup-Jensen L, et al. (2001) Pregnancy-associated plasma protein-A (PAPP-A) cleaves insulin-like growth factor binding protein (IGFBP)-5 independent of IGF: implications for the mechanism of IGFBP-4 proteolysis by PAPP-A. FEMS Lett 504: 36-40. [Crossref]

10. Randhawa R (2008) The insulin-like growth factor system and fetal growth restriction. Pediatr Endocrinol Rev 6: 235-240. [Crossref]

11. Cleemputt DR (1998) Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol 140: 19-24. [Crossref]

12. van Kleffens M, Groffen C, Lindenbergh-Kortleve DJ, van Neew SW, Gonzalez-Parra S, et al. (1998) The IGF system during fetal-placental development of the mouse. Mol Cell Endocrinol 140: 129-136. [Crossref]

13. Irwin JC, Suen LF, Martina NA, Mark SP, Giudice LC (1999) Role of the IGF system in trophoblast invasion and pre-eclampsia. Hum Reprod 2: 90-96. [Crossref]

14. Oboh AO, Patel KR, Spitalnik A, Oboh L, Hueettner P (2014) Placental pathology, first-trimester biomarkers and adverse pregnancy outcomes. J Perinatol 34: 186-191. [Crossref]

15. Costa SL, Proctor L, Dodd JM, Toal M, Okun N, et al. (2008) Screening for placental abnormalities in small-for-gestational-age fetuses. Br J Obstet Gynaecol 89: 352-357. [Crossref]

16. Khong T, De Wolf F, Robertson W, Brosens I (1987) Inadequate maternal vascular response to placentation in pregnancies complicated by preeclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 94: 1464-1466. [Crossref]

17. Smith GC, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, et al. (2002) Early first trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin as predictors of pregnancy complications. BJOG 109: 1265-1270. [Crossref]

18. Robson S C, Martin W L, Morris R K (2014) The investigation and management of the small-for-gestational-age fetus. Greenwood nopt. no. 31: Royal College of Obstetrics and Gynaecology, London UK. 1-33 p.

19. Elfron B, Haste T, Johnstone I, Tibshirani R (2004) Least angle regression. Ann Stat 32: 407-499. [Crossref]

20. Johnson MR, Riddle AF, Grudzinskas JG, Sharma V, Collins WP, et al. (1993) Reduced circulating placental protein concentrations during the first trimester are associated with preterm labour and low birth weight. Hum Reprod 8: 1942-1947. [Crossref]

21. Morssink LP, Kornman LH, Hallawan TH, Kloosterman MD, Beehuks JR, et al. (1998) Maternal serum levels of free beta-hCG and PAPP-A in the first trimester of pregnancy are not associated with subsequent fetal growth retardation or preterm delivery. Prenat Diagn 18: 147-52. [Crossref]

22. Ony C, Liao AW, Spencer K, Munim S, Nicolaides KH (2000) First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. BJOG 107: 1265-1270. [Crossref]

23. Tul N, Pusenjak S, Oresdjar J, Spencer K, Novak-Antolic Z (2003) Predicting complications of pregnancy with first-trimester maternal serum free-beta-hCG, PAPP-A and inhibit-A. Prenat Diagn 23: 990-996. [Crossref]

24. Yaron Y, Heifetz S, Oshohum Y, Lehavi O, Orr-Utregger A (2002) Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome. Prenat Diagn 22: 778-782. [Crossref]

25. Krantz D, Goetzl L, Simpson JL, Thom E, Zachary J, et al. (2004) Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol 191: 1452-1458. [Crossref]

26. Smith GC, Stenhouse EJ, Crossley JA, Ati肯 DA, Cameron AD, et al. (2002) Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab 87: 1762-1767. [Crossref]

27. Spencer K, Cowans NJ, Avigdou K, Molina F, Nicolaides KH (2008) First trimester biochemical markers of aneuploidy and the prediction of small-for-gestational age fetuses. Ultrasound Obstet Gynecol 31: 15-19. [Crossref]

28. Dune B, Dune C, Kiray M, Catin A, Koldas M, et al. (2010) Correlation between first-trimester maternal serum markers, second-trimester uterine artery doppler indices and pregnancy outcome. Gynecol Obstet Invest 70: 126-131. [Crossref]

29. Spencer K, Cowans NJ, Molina F, Kagan KO, Nicolaides KH (2008) First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery. Ultrasound Obstet Gynecol 31: 147-152. [Crossref]

30. Stout MJ, Goetzyer KR, Tuuli MG, Cahill AG, Macones GA, et al. (2013) First trimester serum analytes, maternal characteristics and ultrasound markers to predict pregnancies at risk for preterm birth. Placenta 34: 14-19. [Crossref]

31. Kirkegaard I, Uldburg N, Petersen OB, Torring N, Henrikson TB (2010) PAPP-A, free beta-hCG, and early fetal growth identify two pathways leading to preterm delivery. Prenat Diagn 30: 956-963. [Crossref]

32. Beta J, Akolekar R, Ventura W, Syngelaki A, Nicolaides KH (2011) Prediction of spontaneous preterm delivery from maternal factors, obstetric history and placental perfusion and function at 11-13 weeks. Prenat Diagn 31: 75-83. [Crossref]
41. Pihl K, Larsen T, Krebs L, Christiansen M (2008) First trimester maternal serum PAPP-A, beta-hCG and ADAM12 in prediction of small-for-gestational-age fetuses. *Prenat Diagn* 28: 1131-1135. [Crossref]

42. Krantz D, Goetzl L, Simpson JL, Thom E, Zachary J, et al. (2004) Association of extreme first-trimester free human chorionic gonadotropin-ß, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. *Am J Obstet Gynecol* 191: 1452-1458. [Crossref]

43. Spencer CA, Allen VM, Flowerdew G, Dooley K, Dodds L (2008) Low levels of maternal serum PAPP-A in early pregnancy and the risk of adverse outcomes. *Prenat Diagn* 28: 1029-1036. [Crossref]

44. Odibo AO, Zhong Y, Goetzinger KR, Odibo L, Bick JL, et al. (2011) First-trimester placental protein 13, PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of pre-eclampsia. *Placenta* 32: 598-602. [Crossref]

45. Poon LC, Maiz N, Valencia C, Plasencia W, Nicolaides KH (2009) First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. *Ultrasound Obstet Gynecol* 33: 23-33. [Crossref]

46. Smith GCS, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, et al. (2002) Early Pregnancy Levels of Pregnancy-Associated Plasma Protein A and the Risk of Intrauterine Growth Restriction, Premature Birth, Preeclampsia, and Stillbirth. *J Clin Endocrinol Metab* 87: 1762-1767. [Crossref]

47. Scazzocchio E, Figueras F, Crispì F, Meler E, Masoller N, et al. (2013) Performance of a first-trimester screening of preeclampsia in a routine care low-risk setting. *Am J Obstet Gynecol* 208: 203.e1-203.e10. [Crossref]

48. Poon LC, Stratieva V, Piras S, Piri S, Nicolaides KH (2010) Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11-13 weeks. *Prenat Diagn* 30: 216-223. [Crossref]

49. Foidart JM, Munaut C, Chantraine F, Akolekar R, Nicolaides KH (2010) Maternal plasma soluble endoglin at 11-13 weeks’ gestation in pre-eclampsia. *Ultrasound Obstet Gynecol* 35: 680-687. [Crossref]

50. Giguere Y, Masse J, Theriault S, Bujold E, Lafond J, et al. (2015) Screening for pre-eclampsia early in pregnancy: performance of a multivariable model combining clinical characteristics and biochemical markers. *BJOG* 122: 402-410. [Crossref]

51. Wright A, Guerra L, Pellegrino M, Wright D, Nicolaides KH (2016) Maternal serum PAPP-A and free ß-hCG at 12, 22 and 32 weeks’ gestation in screening for pre-eclampsia. *Ultrasound Obstet Gynecol* 47: 762-767. [Crossref]